Aims: Due to bioprosthetic valve degeneration, aortic valve-in-valve (ViV) procedures are increasingly performed. There is no data on long-term outcomes after aortic ViV. Our aim was to perform a large-scale assessment of long-term survival and reintervention after aortic ViV.
Methods and Results: A total of 1,006 aortic ViV procedures performed more than 5 years ago (mean age 77.7±9.7 years; 58.8% male; median STS-PROM score 7.3% [4.2-12.0]) were included in the analysis. Patients were treated with Medtronic self-expandable valves (MSEV, CoreValve/Evolut, Medtronic Inc.) (n=523, 52.0%), Edwards balloon-expandable valves (EBEV, SAPIEN/SAPIEN XT/SAPIEN 3, Edwards Lifesciences) (n=435, 43.2%) and other devices (n=48, 4.8%). Survival was lower at 8 years in patients with small failed bioprostheses (internal diameter [ID] ? 20 mm) compared with those with large failed bioprostheses (ID > 20 mm) (33.2% vs. 40.5%, p=0.01). Independent correlates for mortality included smaller failed bioprosthetic valves (hazard ratio [HR] 1.07 [95% confidence interval {CI} 1.02-1.13]), age (HR 1.21 [95% CI 1.01-1.45]) and non-transfemoral access (HR 1.43 [95% CI 1.11-1.84]). There were 40 reinterventions after ViV. Independent correlates for all-cause reintervention included pre-existing severe prosthesis-patient mismatch (subhazard ratio [SHR] 4.34 [95% CI 1.31-14.39]), device malposition (SHR 3.75 [95% CI 1.36-10.35]), EBEV (SHR 3.34 [95% CI 1.26-8.85]), and age (SHR 0.59 [95% CI 0.44-0.78]).
Conclusions: The size of the original failed valve may influence long-term mortality and the type of the transcatheter valve may influence the need for reintervention after aortic ViV.
###
Notes to editors
Key information
About PCR
The mission of PCR is to serve the needs of each individual patient by helping the cardiovascular community to share knowledge, experience and practice. PCR offers a wide range of other educational meetings and